STERIS offers a resilient, high-quality business model with some premium valuation, benefiting from hard-to-replicate sterilization networks and stable healthcare procedure volumes. Recent quarterly results included on-target 8% organic revenue growth but margin pressure from tariffs, with management raising tariff impact guidance by $10 million. STE stands to gain from stricter ethylene oxide (EtO) regulations, as compliance costs favor large, established players and will drive more outsourcing to its facilities.
